Title :

Intravenous and subcutaneous immunoglobulins-associated eczematous reactions occur with a broad range of immunoglobulins types : a French national multicenter study.

Author(s) :

Voland, Pauline [Auteur]
Barthel, Camille [Auteur]
Nantes Université [Nantes Univ]
Azzouz, Brahim [Auteur]
Hôpital universitaire Robert Debré [Reims] [CHU Reims]
Raison-Peyron, Nadia [Auteur]
Hôpital Gui de Chauliac [CHU Montpellier]
Du-Thanh, Aurélie [Auteur]
Staumont, delphine [Auteur]
Institut de Recherche Translationnelle sur l'Inflammation (INFINITE) - U1286
Jachiet, Marie [Auteur]
Hopital Saint-Louis [AP-HP] [AP-HP]
Soria, Angèle [Auteur]
CHU Tenon [AP-HP]
Nosbaum, Audrey [Auteur]
Centre Hospitalier Lyon Sud [CHU - HCL] [CHLS]
Valois, Aude [Auteur]
Université de Toulon [UTLN]
Leleu, Camille [Auteur]
Hôpital général (CHU Dijon)
Lebrun-Vignes, Bénédicte [Auteur]
CHU Pitié-Salpêtrière [AP-HP]
Trenque, Thierry [Auteur]
Université de Reims Champagne-Ardenne [URCA]
Hettler, Dominique [Auteur]
Université de Reims Champagne-Ardenne [URCA]
Bernier, Claire [Auteur]
Nantes Université [Nantes Univ]
Viguier, Manuelle [Auteur]

Journal title :

Journal of The American Academy of Dermatology

Abbreviated title :

J Am Acad Dermatol

Volume number :

88

Pages :

380-387

Publication date :

2022-10-26

ISSN :

1097-6787

English keyword(s) :

dermatitis
dyshidrosis
eczema
erythema
intravenous immunoglobulins
polyradiculoneuritis
subcutaneous immunoglobulins

HAL domain(s) :

Sciences du Vivant [q-bio]

English abstract : [en]

Background Human immunoglobulins are used for treating diverse inflammatory and autoimmune disorders. Eczema is an adverse event reported but poorly described. Objectives To describe the clinical presentation, severity, ...
Show more >Background Human immunoglobulins are used for treating diverse inflammatory and autoimmune disorders. Eczema is an adverse event reported but poorly described. Objectives To describe the clinical presentation, severity, outcome, and therapeutic management of immunoglobulin-associated eczema. Methods This retrospective and descriptive study included a query of the French national pharmacovigilance database, together with a national call for cases among dermatologists. Results We included 322 patients. Eczema occurred preferentially in men (78.9%) and in patients treated for neurological pathologies (76%). The clinical presentation consisted mainly of dyshidrosis (32.7%) and dry palmoplantar eczema (32.6%); 5% of cases exhibited erythroderma. Sixty-two percent of the eczema flares occurred after the first immunoglobulin course. Eczema was observed with 13 intravenous or subcutaneous immunoglobulin types and recurred in 84% of patients who maintained the same treatment and in 68% who switched the immunoglobulin type. After immunoglobulin discontinuation, 30% of patients still had persistent eczema. Limitations Retrospective study, with possible missing data or memory bias. Conclusion Immunoglobulin-associated eczema occurred with all immunoglobulin types, preferentially in patients with neurologic diseases who required prolonged immunoglobulin treatment. Recurrence was frequent, even after switching the immunoglobulin type, which can lead to a challenging therapeutic situation when immunoglobulin maintenance is required.Show less >

Language :

Anglais

Audience :

Internationale

Popular science :

Non

Administrative institution(s) :

Université de Lille
Inserm
CHU Lille

Collections :

• Institut de Recherche Translationnelle sur l'Inflammation (INFINITE) - U1286

Submission date :

2024-01-12T00:22:11Z
2024-03-21T12:33:28Z